Aug 9, 2013
ANI Pharmaceuticals Reports Net Revenues of $6.2 million and adjusted ...
Second quarter net revenues of $6.2 million increased 19% versus $5.2 million for the same period in 2012.
ANI Pharmaceuticals, Inc. Announces Name Change and Reverse Stock Split
ANI furthermore announced that its Board of Directors yesterday approved a reverse split of its common stock and Class C special stock at a ratio of one share for every six shares of stock outstanding, and a proportional decrease in ANI's authorized common stock, Class C special stock and preferred stock.
BioSante Hires VP of New Business Development and Contract...
BioSante Pharmaceuticals, Inc. today announced that it has hired Robert Schrepfer as Vice President of New Business Development and Contract Manufacturing, with an effective start date of August 12, 2013.